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In the two positive studies described above [4,6], the use of adjuvant 
cisplatin/vinorelbine was associated with signiﬁcant toxicity (severe 
neutropenia [grade 3/4] in > 80% of patients and febrile neutropenia 
in > 8-10% of patients) and only few patients could receive treatment 
as scheduled. Therefore, the schedule of administration of vinorelbine 
of these studies is not routinely used. Nevertheless, it is possible that if 
vinorelbine was given by the more widely used schedule (days 1 and 8 
every 3 weeks) it may have been more active. 
Currently, the available evidence suggests that the best candidates for 
adjuvant therapy are those patients who have undergone lobectomy, 
those who have made a complete recovery from surgery, have no severe 
comorbidities, are aged < 70 years and have a performance status of 0 
or 1. Two further issues that need to be addressed in future research are 
the potential differences in survival between smokers and never smok-
ers, and the effect on prognosis of the absence or presence of vascular 
invasion. It is becoming clear that tumors in non-smokers differ from 
those in smokers in terms of histology and possibly prognosis. This 
could have implications for the risk of recurrence and hence the value 
of adjuvant therapy. Similarly, the presence or absence of vascular in-
vasion may inﬂuence the risk of recurrence and hence whether adjuvant 
therapy is likely to be beneﬁcial. 
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Studies of postoperative irradiation show that it does not improve 
results in patients who have no evidence of metastasis to the hilar or 
mediastinal lymph nodes. In fact, postoperative irradiation might have 
a net deleterious effect on survival according to the post operative 
radiation therapy (PORT) meta analysis. Shields observed that local re-
currence was infrequent in the case of a pathologically complete resec-
tion with no evidence of regional lymph node metastasis, so irradiation 
would accomplish little for such patients. Moreover, radiation therapy 
may place an additional burden on pulmonary function, especially in 
patients who have required pneumonectomy. A meta-analysis reiterated 
the long-recognized potential for adverse effects of radiation therapy 
when rigorous CT-based treatment planning is not done. 
Several retrospective studies have suggested that postoperative ir-
radiation can improve outcome when mediastinal nodal metastases are 
present. An analysis of postoperative radiation therapy in available pro-
spective trials, most of which was not based on CT planning, showed 
neither a detrimental nor a beneﬁcial effect. On the basis of the striking 
improvement in local control of squamous cell carcinoma shown by the 
Lung Cancer Study Group, the Eastern Cooperative Oncology Group 
(ECOG) coordinated a large intergroup trial to compare postoperative 
radiation therapy plus concurrent chemotherapy with cisplatin and 
etoposide to postoperative radiation therapy alone. In initial results for 
373 patients eligible for analysis and a median follow-up of 44 months, 
the median survival was 42 months for patients given only radiation 
and 38 months for those given combined-modality treatment (P = 0.48). 
No signiﬁcant differences were found in failure patterns between the 2 
study groups. Therefore, although postoperative irradiation can clearly 
reduce the risk of local recurrence in patients with mediastinal node 
metastasis, its effect on survival (with or without adjuvant chemothera-
py) is still under investigation. 
Finally, Sawyer and others studied patients with stage IIIA (N2) 
NSCLC using regression tree analysis to identify patients at low, inter-
mediate, and high risk of local recurrence. Numbers of involved lymph 
nodes, locations of mediastinal lymph nodes relative to the location of 
the primary tumor, and T stage were used to identify intermediate- and 
high-risk groups. Excluding the low-risk group, postoperative radiation 
therapy conferred a highly signiﬁcant improvement in local recurrence-
free and overall survival rates. This approach can form the basis for fu-
ture studies of the value of postoperative irradiation and chemotherapy.
Controversy continues regarding the most effective treatment for pa-
tients with marginally resectable NSCLC. A retrospective review of pa-
tients treated at The University of Texas M. D. Anderson Cancer Center 
conﬁrmed the impression that patients with more favorable disease 
are selected for surgical intervention. Two small prospective studies 
provided quite similar results suggesting that induction chemotherapy 
improves survival in patients with resectable NSCLC. Important as-
pects of post-operative radiotherapy are patients selection
(N2 NSCLC and lobectomy patients rather than pneumonectomy 
patients). Those patients with N2 NSCLC who require pneumonectomy 
should be treated by chemoradiotherapy to avoid lung toxicity. Careful 
CT/PET based post-pretaive radiotherapy is essential to target positive 
mediastinal nodes without irradiating residual lung . Now we are able 
to SPECT to ﬁnd the part of the functional lung where irradiation needs 
to be avoided. If there was microscopic positive margin left, post opera-
tive radiotherapy needs to be given with minimal 60 Gy in 30 fractions 
and concurrent cisplatin based chemotherapy. For the negative margin 
and N2 patients, 50 Gy in 25 fractions will be given with conformal ra-
diation therapy technique. The lung heterogeneity correction should be 
considered as well as dose volume histogram. The lung volume needs 
to be lea than 40 % at V20 if post-operative radiotherapy will be given. 
If concurrent chemoradiotherapy is required because of the positive 
margins, V20 should be less than 35% to avoid treatment related pneu-
monitis. These patients with microscopic N2 disease might live long 
enough to manifest cardiac toxicity. Therefore avoidance of the large 
volume cardiac irradiation is also essential among patients who already 
have high risk of cardiovascular disease due to smoking. Because of the 
mediastinal nodal irradiation, not all patients need 4DCT.
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Future investigation is required to ﬁnd which modality (adjuvant 
chemotherapy vs. radiotherapy) needs to be given immediately after 
surgery for those with N2 disease and negative margin. 
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Accurate staging of the mediastinum in non-small cell lung cancer is 
essential to appropriately determine if patients should be candidates for 
surgical resection, neo-adjuvant therapy, or for deﬁnitive chemoradia-
tion. It has been shown that patients with persistent, bulky N2 disease 
following induction therapy have poor survival if they go on to surgery. 
Thus, re-staging patients after induction therapy is becoming even more 
important; however, the ideal method of staging the mediastinum is 
still under debate. With the continued development of new minimally 
invasive techniques, such as endobronchial ultrasound (EBUS) guided 
transbronchial needle biopsy and VATS staging, the question is sure to 
evolve.
Mediastinoscopy.
Cervical mediastinoscopy is the current gold standard for mediastinal 
staging. Pooling data from several studies, Toloza et al, found that 
cervical mediastinoscopy had a sensitivity of 81% and speciﬁcity 
approaching 100%; for a positive predictive value of 1.0 and nega-
tive predictive value of 0.91.1 In contrast, PET had an overall positive 
predictive value of 0.79 and negative predictive value of 0.93.2 The 
main risk with PET is that some patients with pathologically negative 
mediastinal disease may continue to have FDG-avid lymph nodes. 
Thus, some patients with potentially curable disease will be denied 
surgical intervention. Standard cervical mediastinoscopy is not able to 
sample aortopulmonary window, paraesophageal, and pulmonary liga-
ment nodes. Other drawbacks include the need for general anesthesia, 
the risk of bleeding, and risk of recurrent laryngeal nerve injury. 
Chamberlain Procedure and Video-Assisted Thoracic Surgery 
(VATS)
A left anterior parasternal mediastinotomy, or Chamberlain procedure, 
provides access to the subaortic space, however, generally requires 
division of costal cartilage. The sensitivity and speciﬁcity are 74% 
and 100% respectively. VATS also allows sampling of the AP window 
nodes. If performed at the time of deﬁnitive resection, an initial VATS 
sampling of ipsilateral mediastinal lymph nodes with frozen section 
may prevent the surgeon from going on to perform an unnecessary 
resection. There have been relatively little data comparing the accuracy 
of VATS staging to either PET or conventional mediastinoscopy. Like 
mediastinoscopy, these procedures require general anesthesia and carry 
a risk of bleeding.
Endoscopic and endobronchial ultrasound.
Endoscopic ultrasound guided ﬁne-needle aspiration (EUS-FNA) 
allows access to left sided paratracheal nodes, as well as para-aortic, 
subcarinal, para-esophageal, and sometimes inferior pulmonary liga-
ment nodes. For these lymph nodes, EUS-FNA has been shown to have 
comparable sensitivity and speciﬁcity to CT and PET. The diagnostic 
accuracy is further increased if there is lymph node enlargement. En-
dobronchial ultrasound (EBUS) is a relatively newer method of staging 
that uses an ultrasound transducer mounted on a videobronchoscope to 
guide FNA. It can be used to biopsy paratracheal, subcarinal, and peri-
bronchial nodes; in experienced hands, even some AP window nodes 
can be biopsied safely. In the few published case series, the sensitivity 
and speciﬁcity are roughly 85% and 100% respectively. Both EUS and 
EBUS can be done relatively quickly, without general anesthesia, and 
with a minimal complication rate. Combined, EUS and EBUS have the 
potential to accurately stage the entire mediastinum with low morbidity. 
Overview
The role for invasive staging of the mediastinum continues to evolve 
as new technologies emerge. Randomized trials comparing the newer 
methods with established methods are necessary. Although it is yet 
unclear which method or methods will become the new standard, all 
these invasive approaches have one distinct advantage over non-in-
vasive methods like CT or PET - access to tissue. For patients with 
mediastinal disease, these procedures can be used to make a deﬁni-
tive tissue diagnose at the same time as staging, which is required for 
initiation of induction therapy. In addition, as molecular proﬁling of 
tumors becomes more important, being able to analyze the biology of 
the tumor (both pre- and post-induction) may add another dimension to 
individually tailored treatment regimens. 
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Investigations of novel agents remain a cornerstone of clinical research 
in Oncology. Guidelines for investigations of novel agents have existed 
for many years. They include sequential investigations of a novel agent 
in the phase I, II and III setting. It is clear that the classical phase II 
study design is not particularly well suited to investigations of targeted 
agents since it may not result in measurable objective responses. Al-
ternative trial designs have been investigated over recent years. These 
include a randomized phase II trials as well as randomized discontinu-
ation trials and dose range trials. Examples of such studies and their 
impact on recent drug development will be presented. 
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A Medical Doctor studies for longer than most any other profession. 
The reason for this is that there is a considerable amount of knowledge 
required in order to be able to provide a correct diagnosis and cure 
to patients in his area of speciality. If diagnostic part of his activity is 
directly related to clinical practice (academic and/or private), the imple-
mentation of this activity requires a medically driven/controlled admin-
istrative organization. The dramatic improvement, technicality, cost and 
speciﬁcity of diagnostic procedures make the role of a single physician 
less and less predominant and the need for regulation more and more 
important. A medical input is necessary to determine which procedures 
are the most appropriate and should be available for all patients.
